Skip to Main Content

Amid ongoing concern that Covid-19 therapies and vaccines may be unaffordable, a bipartisan group of lawmakers introduced a pair of bills that would prohibit drug makers from price gouging and also require all taxpayer-funded Covid-19 research to be recorded in a federal database.

The move comes as access to Covid-19 medical products emerges as a hot-button issue in the U.S. and elsewhere, with worries mounting over the extent to which a therapy or vaccine will be available in sufficient quantities at affordable prices. In February, Health and Human Services Secretary Alex Azar told Congress the Trump administration wanted to make products affordable, but could not control pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!